Production & Sales

Lilly to acquire Loxo Oncology for $8bn

Eli Lilly and Company (Lilly) has agreed to acquire Connecticut-based biopharmaceutical company Loxo Oncology in an all-cash deal worth $8bn.

Catalent to invest $200m in biologics business

Catalent, a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has started a $200m capital investment to expand biologics capacity and capabilities.

Bristol-Myers Squibb to acquire Celgene for $74bn

Pharma giant Bristol-Myers Squibb has agreed to acquire US biotechnology company Celgene in a cash-cum-stock deal worth around $74bn.

Nuvo Pharmaceuticals completes acquisition of revenue-generating products from Aralez

Canadian healthcare company Nuvo Pharmaceuticals has completed the previously announced acquisition of a portfolio of more than 20 revenue-generating products from Aralez Pharmaceuticals.

Portola secures FDA approval for Andexxa generation 2 manufacturing process

The US Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for the manufacturing process of second generation Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo].

Opiant and Sanofi sign licensing deal for drinabant

Opiant Pharmaceuticals has signed a licensing agreement with Sanofi for the development and commercialisation of drinabant across the globe for the treatment of acute cannabinoid overdose (ACO).

Lupin awards MALT1’s licensing rights to AbbVie

Indian pharmaceutical company Lupin has awarded the licensing rights of its Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1) programme to AbbVie.

Taisho offers to buy BMS’ UPSA consumer health business for $1.6bn

Taisho Pharmaceutical has offered $1.6bn to acquire UPSA consumer health business from Bristol-Myers Squibb (BMS).

Pfizer, GSK to create $13bn consumer healthcare joint venture

Pfizer and the UK-based GlaxoSmithKline (GSK) have agreed to merge their respective consumer healthcare businesses into a new joint venture (JV), which will be majority owned by the latter.